Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 286

1.

Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV.

Pradat P, Huleux T, Raffi F, Delobel P, Valantin MA, Poizot-Martin I, Pugliese P, Reynes J, Rey D, Hoen B, Cabie A, Bani-Sadr F, Cheret A, Duvivier C, Jacomet C, Fresard A, Hustache-Mathieu L, Cotte L; Dat’AIDS study Group.

AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001789. [Epub ahead of print]

PMID:
29438195
2.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 Feb 1. doi: 10.1111/hiv.12581. [Epub ahead of print]

PMID:
29388732
3.

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.

Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group .

J Antimicrob Chemother. 2018 Jan 22. doi: 10.1093/jac/dkx498. [Epub ahead of print]

PMID:
29365125
4.

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G; ANRS 144 Inter-ACTIV study group.

Lancet HIV. 2018 Jan 9. pii: S2352-3018(18)30002-X. doi: 10.1016/S2352-3018(18)30002-X. [Epub ahead of print]

PMID:
29329763
5.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2017 Dec 22. doi: 10.1111/hiv.12573. [Epub ahead of print]

PMID:
29271606
6.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.

Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group.

BMC Med. 2017 Dec 18;15(1):217. doi: 10.1186/s12916-017-0979-1.

7.

Hospitalization of HIV positive patients: Significant demand affecting all hospital sectors.

Seng R, Mutuon P, Riou J, Duvivier C, Weiss L, Lelievre JD, Meyer L, Vittecoq D, Zak Dit Zbar O, Frenkiel J, Frank-Soltysiak M, Boue F, Rapp C, Sobel A, Brucker G, Goujard C, Salmon D; COREVIH.

Rev Epidemiol Sante Publique. 2017 Dec 9. pii: S0398-7620(17)30525-4. doi: 10.1016/j.respe.2017.08.002. [Epub ahead of print]

PMID:
29233572
8.

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group.

HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7.

PMID:
29214737
9.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3502. doi: 10.1093/jac/dkx383. No abstract available.

PMID:
29121210
10.

Potential Role of Vδ2+ γδ T Cells in Regulation of Immune Activation in Primary HIV Infection.

Bhatnagar N, Girard PM, Lopez-Gonzalez M, Didier C, Collias L, Jung C, Bollens D, Duvivier C, Von Platen C, Scott-Algara D, Weiss L; ANRS EP-56 Group.

Front Immunol. 2017 Sep 25;8:1189. doi: 10.3389/fimmu.2017.01189. eCollection 2017.

11.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.

HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6.

12.

Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).

Nordmann S, Vilotitch A, Roux P, Esterle L, Spire B, Marcellin F, Salmon-Ceron D, Dabis F, Chas J, Rey D, Wittkop L, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group.

J Viral Hepat. 2018 Feb;25(2):171-179. doi: 10.1111/jvh.12797. Epub 2017 Nov 20.

PMID:
28984055
13.

Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.

Lê MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard JP, Duvivier C, Peytavin G, Launay O, Ghosn J.

J Antimicrob Chemother. 2017 Nov 1;72(11):3167-3171. doi: 10.1093/jac/dkx275.

PMID:
28961979
14.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression.

Supervie V, Assoumou L, Breban R, Lert F, Costagliola D, Pialoux G, Landman R, Girard PM, Slama L; IMEA 040 DATA Study Group.

J Antimicrob Chemother. 2017 Nov 1;72(11):3172-3176. doi: 10.1093/jac/dkx276.

PMID:
28961977
15.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434. doi: 10.1093/jac/dkx300.

PMID:
28961719
16.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
17.

Ageing with HIV: do comorbidities and polymedication drive treatment optimization?

Cuzin L, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C, Rey D, Poizot-Martin I, Chirouze C, Bani-Sadr F, Cabié A; Dat'AIDS Study Group.

HIV Med. 2017 Jul;18(6):395-401. doi: 10.1111/hiv.12441. Epub 2016 Oct 7.

PMID:
28858437
18.

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2018 Feb;19(2):90-101. doi: 10.1111/hiv.12546. Epub 2017 Aug 31.

PMID:
28857427
19.

No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France.

Cuzin L, Yazdanpanah Y, Huleux T, Cotte L, Pugliese P, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Delpierre C; Dat'AIDS Study Group.

HIV Med. 2018 Mar;19(3):238-242. doi: 10.1111/hiv.12545. Epub 2017 Aug 18.

PMID:
28834136
20.

Detectable HIV-RNA in semen of HIV controllers.

Chaix ML, Boufassa F, Meyzer C, Leruez-Ville M, Mahjoub N, Nere ML, Genet P, Duvivier C, Lascoux-Combes C, Lambotte O, Ghosn J.

PLoS One. 2017 Aug 16;12(8):e0183376. doi: 10.1371/journal.pone.0183376. eCollection 2017.

Supplemental Content

Loading ...
Support Center